Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
10.59
+0.07 (0.67%)
At close: Aug 1, 2025, 4:00 PM
10.66
+0.07 (0.66%)
After-hours: Aug 1, 2025, 5:54 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26.4, which forecasts a 149.29% increase in the stock price over the next year. The lowest target is $21 and the highest is $33.
Price Target: $26.40 (+149.29%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +117.19% | Apr 2, 2025 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +211.61% | Mar 20, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $30 | Buy | Reiterates | $30 | +183.29% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $35 → $25 | Strong Buy | Maintains | $35 → $25 | +136.07% | Mar 20, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $21 | Buy | Maintains | $23 → $21 | +98.30% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
4.91M
from 9.04M
Decreased by -45.74%
Revenue Next Year
17.63M
from 4.91M
Increased by 259.34%
EPS This Year
-2.26
from -5.00
EPS Next Year
-2.46
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.5M | 54.6M | 161.2M | ||
| Avg | 4.9M | 17.6M | 73.4M | ||
| Low | 2.8M | n/a | 34.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5% | 1,012.9% | 814.3% | ||
| Avg | -45.7% | 259.3% | 316.3% | ||
| Low | -68.6% | - | 96.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.93 | -1.82 | -1.34 | ||
| Avg | -2.26 | -2.46 | -2.25 | ||
| Low | -2.56 | -2.87 | -3.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.